Alfred R, Chin S N, Williams E, Walters C, Barton E N, Shah D
Department of Medicine, Faculty of Medical Sciences, The University of the West Indies, Kingston 7, Jamaica, West Indies.
West Indian Med J. 2012 Nov;61(8):795-801.
To identify the prevalence of oestrogen receptor (ER) positivity, and determine the relationship of ER status with patient and tumour characteristics, in patients with breast cancer
A retrospective review was conducted regarding the prevalence and clinical significance of ER in patients with breast cancer at the University Hospital of the West Indies (UHWI). Oestrogen receptor status results of 243 patients treated at UHWI were collected for the period January 1, 2002 to December 31, 2009. One hundred and ninety-nine were available for review.
Oestrogen receptor status was positive in 125 (63%) and negative in 74 (37%) patients. Mean age at diagnosis was 52.6 +/- 13.0 years for the ER positive group and 58.5 +/- 14.23 years for the ER negative group. Postmenopausal women accounted for 55.2% and 64.9% of the ER positive and negative groups, respectively. Mean BMI was 28.0 kg/m2 and 29.6 kg/m2 for the ER positive and negative groups, respectively. Menarche occurred mainly between ages 12 and 13 years for both groups. Mean age at 1st parity was 23.4 years for the ER positive and 21.4 years for the ER negative group with median parity of two for both groups. The most prevalent risk factors were oral contraceptive pill (OCP) use (24.3% for the ER positive group, 17.1% for the ER negative group), family history of breast cancer (12.0%; 13.4%) and previous smoking (8.4%; 6.9%). Tumour node metastasis (TNM) stage was Stage II in most cases (46%; 49%). Infiltrating ductal histology was most common (81.5%; 87.7%). Her 2/ neu status was negative for most patients (91.3%; 91.5%). Most patients were disease free (77.6%; 70.0%) after an average follow-up period of 3.5 years. More persons in the ER negative group had locoregional recurrence (8%) and metastases (22%).
Oestrogen receptor positive cohort was more prevalent. The ER negative group was older (p = 0.003).
确定雌激素受体（ER）阳性在乳腺癌患者中的患病率，并确定ER状态与患者及肿瘤特征之间的关系。
对西印度群岛大学医院（UHWI）乳腺癌患者中ER的患病率及临床意义进行回顾性研究。收集了2002年1月1日至2009年12月31日期间在UHWI接受治疗的243例患者的雌激素受体状态结果。其中199例可供分析。
125例（63%）患者雌激素受体状态为阳性，74例（37%）为阴性。ER阳性组诊断时的平均年龄为52.6±13.0岁，ER阴性组为58.5±14.23岁。绝经后女性在ER阳性组和阴性组中分别占55.2%和64.9%。ER阳性组和阴性组的平均体重指数分别为28.0kg/m²和29.6kg/m²。两组月经初潮主要发生在12至13岁之间。ER阳性组首次生育的平均年龄为23.4岁，ER阴性组为21.4岁，两组的中位产次均为2次。最常见的危险因素是口服避孕药（OCP）的使用（ER阳性组为24.3%，ER阴性组为17.1%）、乳腺癌家族史（12.0%；13.4%）和既往吸烟（8.4%；6.9%）。大多数病例的肿瘤淋巴结转移（TNM）分期为II期（46%；49%）。浸润性导管组织学最为常见（81.5%；87.7%）。大多数患者的Her 2/neu状态为阴性（91.3%；91.5%）。在平均3.5年的随访期后，大多数患者无疾病（77.6%；70.0%）。ER阴性组中局部区域复发（8%）和转移（22%）的患者更多。
雌激素受体阳性队列更为常见。ER阴性组年龄更大（p = 0.003）。
